Effect of Some Psychotropic Drugs on Luminol

Total Page:16

File Type:pdf, Size:1020Kb

Effect of Some Psychotropic Drugs on Luminol Effect of Some Psychotropic Drugs on Luminol Ð Dependent Ð ț Chemiluminescence Induced by O2 , OH, HOCl Vera Hadjimitova*, Trayko Traykov, Milka Mileva and Stefan Ribarov Department of Medical Physics and Biophysics, Sofia University School of Medicine, Sofia 1431, Bulgaria, Fax: +359-2-517-176. E-mail: [email protected] * Author for correspondence and reprint requests Z. Naturforsch. 57c, 1066Ð1071 (2002); received June 6/July 15, 2002 Chemiluminescence, Free Radicals, Psychotropic Drugs We studied antioxidant activity of six neuroleptics (chlorpromazine, levomepromazine, promethazine, trifluoperazine and thioridazine) and two antidepressants (imipramine and amitriptyline) in the range of concentration of 10Ð7Ð10Ð4 m. We applied luminol-dependent chemiluminescence to test the ability of these drugs to scavenge the biologically relevant oxygen-derived species: hydroxyl radical, superoxide radical, hypochlorous acid in vitro. We found that the phenothiazines were powerful scavengers of hydroxyl and superoxide radicals. Chlorprothixene, amitriptyline and imipramine had no scavenge activity to the superoxide radical. All drugs showed a moderate scavenger effect on hypochloric anion. α Introduction might inactivate 1-antiproteinase at the spot of Reactive oxygen radicals have been implicated inflammation and it contributes to protiolitic dam- in pathophysiology of many neurologic disorders ages though HOCl has a secondary role on bacte- and brain dysfunction (Kontos and George, 1985; ricide effect of phagocytes. Siesjo et al., 1989; Chan, 1994). The evidence The phenothiazines Ð their most widely known shows that reactive oxygen radicals are involved representative being chlorpromazine (CPZ) Ð and in brain injuries such as cerebral ischemia and re- their metabolites are distributed in many body tis- perfusion (Chan, 2001). It has been demonstrated sues reaching highest concentration in brain, lung, that approximately 2% to 5% of the electron flow liver and spleen (AHFS Drug Information 89). in isolated brain mitochondria produces superox- The common therapeutic plasma concentration of Ð these drugs is usually in the range of 0.05Ð5 µm in ide anion radicals (O2 ) and hydrogen peroxide the brain the concentration is about two times big- (H2O2) (Boveris and Chance, 1973). These con- stantly produced reactive oxygen species (ROS) ger (Krushkov and Lambev 1993). The main ther- are reduced by enzyme and nonenzyme antioxi- apeutic effect of CPZ is realized mostly at treat- dant protective systems of organism. Far more re- ment of psychic disorders. It is established active hydroxyl radicals (țOH) are generated at however that CPZ inhibits lipid peroxidation in - disturbance of the balance upon increase of the vivo (Roy et al., 1984) and in vitro (Slater, 1968). Ð CPZ and trifluoperazine (TFPZ) protect the myo- concentration of O2 and H2O2. The invasion of phagocytes at the spot of the damaged or inflamed cardial phospholipids from LP connected with tissue results in local increase of ROS concentra- ischemic tissue damages (Janero and Burghardt, tion. Together with the increased production of 1989). As far as initiation and development of LP Ð is connected with availability of ROS, the manifes- O2 and H2O2, HOCl is also produced. HOCl tation of antioxidant properties could be ascribed to the ability of drugs to scavenge ROS. Abbreviations:O2, superoxide radical; KO2, potassium Our aim was to establish the capability of a group superoxide; țOH, hydroxyl radical; ROS, reactive oxy- gen species; NaOCl, sodium hypochlorite; CL, chemilu- widely used psychotropic drugs to interact with minescence; CPZ, chlorpromazine; LVPZ, levomepro- ROS in vitro by means of luminol-dependent mazine; TRDZ, thioridazine; PMZ, promethazine; chemiluminescence (CL). The present paper covers TFPZ, trifluoperazine; CPX, chlorprothixene; AMI, am- the investigations on the ability of neuroleptics: itriptyline; IMI, imipramine; PBS, phosphate buffer solu- tion; CL-SI, chemiluminescence scavenging index; LP, chlorpromazine (CPZ), promethazine (PMZ), le- lipid peroxidation. vomepromazine (LVPZ),thioridazine (TRDZ), tri- 0939Ð5075/2002/1100Ð1066 $ 06.00 ” 2002 Verlag der Zeitschrift für Naturforschung, Tübingen · www.znaturforsch.com · D V. Hadjimitova et al. · Psychotropic Drugs and Chemiluminescence in Model Systems 1067 fluoperazine (TFPZ), chlorprothixene (CPX) and control sample, drug was omitted. Each sample antidepressants: imipramine (IMI), amitriptyline was incubated for 10 min. at 37 ∞C. Then, 20 µlof Ð ț (AMI) to scavenge O2 , OH and HOCl. xanthine oxidase (100 IU/l in PBS) were added (one unit xanthine oxidase will convert 1.0 µmol of Materials and Methods xanthine to uric acid per min at pH 7.5 at 25 ∞C). Subsequently, the CL signal was measured for Chemicals and preparations 5 min. The ratio of CL in the presence and in the The following psychotropic drugs were studied: absence of the drug was termed CL scavenging phenothiazines (chlorpromazine, levomepromazi- index (CL-SI). ne, thioridazine, promethazine and trifluopera- zine), three-cycled antidepressants-imipramine Luminol-dependent CL in a system of potassium and amitriptyline, and thioxanthene neuroleptic- superoxide (KO2) Ð produced superoxide (assay II) chlorprothixene. Chlorpromazine, thioridazine, The assay was carried out using 1 ml samples of promethazine hydrochlorides and trifluoperazine PBS, pH 7.4, containing 0.1 mm luminol and the dihydrochloride were obtained from Sigma Chem- drug (in control sample, drug was omitted). The ical Co. (St. Louis, MO, USA). Levomepromazine CL was measured immediately after addition of (2-methoxy-10-[3-dimethylamino-2-methylpropyl]- 20 µlKO solution. In this case the release of the phenothiazine) hydrochloride was kindly donated 2 superoxide is a fast process. Therefore, CL was by Pharmachim Co. (Sofia, Bulgaria). Chlorpro- measured using the “flash assay” option of the thixene, amitriptyline and imipramine were ob- MultiUse program, every 50 milliseconds. The tained from Sigma Chemical Co. (St. Louis, MO, ratio of CL in the presence and in the absence of USA). Sodium hypochlorite and most of the other the drug was termed CL scavenging index (CL- reagents were obtained from Sigma Chemical Co. SI). (St. Louis, MO, USA) and were of finest grade. The chemiluminescence reagent was prepared Luminol-dependent CL in a system of iron-depen- by dissolving luminol in a small amount of 0.01 m dent hydroxyl radical formation (assay III) NaOH. Then the solution was diluted to luminol concentration of 1 mm with a 50 mm phosphate One ml samples of PBS, pH 7.4, containing: 3+ buffer solution (PBS) and the pH was adjusted to 0.1 mm luminol, 0.1 mm Fe , 0.1 mm EDTA, 7.4 with 0.01 m HCl. 0.1 mm ascorbate, 1 mm H2O2 and either of tested Drugs were dissolved in PBS, pH 7.4. Their final drug at concentrations between 1 and 100 µm,ora concentrations in the samples investigated are buffer for the controls. The CL was measured shown in the Figure legends. using the “flash assay” option of the MultiUse program, every 50 milliseconds. The ratio of CL in Methods the presence and in the absence of the drug was termed CL scavenging index (CL-SI). Luminol-dependent CL was used for registration of ROS (Allen, 1975; Allen and Loose, 1976; Itoh et Luminol-dependent CL in a system of NaOCl- al., 1989). For this purpose an LKB 1251 lumino- generated hypochlorite (assay IV) meter (Bioorbit, Turku, Finland) set at 37 ∞C was used. It was connected with an AT-type computer The sample contained the following substances via serial interface and MultiUse program ver. 1.08 in 1 ml PBS: 0.1 mm luminol 0.06 mm NaOCl and (Bioorbit, Turku, Finland) was used for collecting the tested drug at concentrations between 1 and µ of the data. Four types of CL assays were used. 100 m, or a buffer for the controls. The chemilu- minescence was registered after addition of NaOCl using the “flash assay” option of the Luminol-dependent CL in a system of xanthine- MultiUse program, every 50 milliseconds. The ra- xanthine oxidase-generated superoxide (assay I) tio of CL in the presence and in the absence of One ml PBS, pH 7.4, containing 0.1 mm luminol, the drug was termed CL scavenging index (CL- 1mm xanthine and the drug at concentrations as SI). indicated in the figure legends were used. In the 1068 V. Hadjimitova et al. · Psychotropic Drugs and Chemiluminescence in Model Systems Results and Discussion gram every 50 milliseconds. The results obtained are summarized in Fig. 2a. We did not find any The effects of drugs on the luminol-dependent significant changes of CL-SI below drug concen- Ð µ CL in a system with enzymatically generated O2 trations of 10 m. At higher concentrations, CPZ, (assay I) are shown in Fig. 1. We assume that the PMZ and TFPZ slightly reduced CL-SI. At the CL ratio in the presence and in the absence of concentration of 0.1 mm, the phenothiazines de- Ð the tested drugs should show the O2 scavenging creased CL-SI 2.5 to 6.5-fold. properties of the drugs. Therefore, this ratio was Figurs 1b. and 2b. show data concerning the effect termed CL-SI (chemiluminescence scavenging in- of the CPX, IMI and AMI on the luminol-depen- dex). dent CL in a xanthine-xanthine oxidase and KO2 µ Ð At concentrations above 1 m, phenothiazines system of O2 generation. The results obtained de- decreased moderately CL-SI in a xanthine-xan- monstrate that the CPX, AMI and IMI in the sys- thine oxidase system. The effect was most distinct tems do not affect substantially the CL-response. for CPZ, while being vague for TFPZ. These re- The results obtained show that at concentrations sults possibly indicate that phenothiazines were lower than 10 µm, the investigated drugs do not ex- Ð able to scavenge O2 . hibit a detectable scavenging effect. Drug-induced decrease of the luminol-depen- The formation of țOH is achieved in most of the Ð dent CL in a system of xanthine-xanthine oxidase- O2 generating systems, in particular by activated generated superoxide radicals may be due to the phagocytes.
Recommended publications
  • Deanxit SPC.Pdf
    SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Deanxit film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: Flupentixol 0.5 mg (as 0.584 mg flupentixol dihydrochloride) Melitracen 10 mg (as 11.25 mg melitracen hydrochloride) Excipients with known effect: Lactose monohydrate For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablets. Round, biconvex, cyclamen, film-coated tablets. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Anxiety Depression Asthenia. Neurasthenia. Psychogenic depression. Depressive neuroses. Masked depression. Psychosomatic affections accompanied by anxiety and apathy. Menopausal depressions. Dysphoria and depression in alcoholics and drug-addicts. 4.2 Posology and method of administration Posology Adults Usually 2 tablets daily: morning and noon. In severe cases the morning dose may be increased to 2 tablets. The maximum dose is 4 tablets daily. Older people (> 65 years) 1 tablet in the morning. In severe cases 1 tablet in the morning and 1 at noon. Maintenance dose: Usually 1 tablet in the morning. SPC Portrait-REG_00051968 20v038 Page 1 of 10 In cases of insomnia or severe restlessness additional treatment with a sedative in the acute phase is recommended. Paediatric population Children and adolescents (<18 years) Deanxit is not recommended for use in children and adolescents due to lack of data on safety and efficacy. Reduced renal function Deanxit can be given in the recommended doses. Reduced liver function Deanxit can be given in the recommended doses. Method of administration The tablets are swallowed with water. 4.3 Contraindications Hypersensitivity to flupentixol and melitracen or to any of the excipients listed in section 6.1.
    [Show full text]
  • Download Product Insert (PDF)
    PRODUCT INFORMATION Chlorprothixene (hydrochloride) Item No. 20772 CAS Registry No.: 6469-93-8 Formal Name: (3Z)-3-(2-chloro-9H-thioxanthen-9-ylidene)-N,N- N dimethyl-1-propanamine, monohydrochloride Synonyms: cis-Chlorprothixene, NSC 169899 MF: C18H18ClNS • HCl Cl FW: 352.3 Purity: ≥98% UV/Vis.: λmax: 230, 270, 329 nm S Supplied as: A crystalline solid • HCl Storage: -20°C Stability: As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly Laboratory Procedures Chlorprothixene (hydrochloride) is supplied as a crystalline solid. A stock solution may be made by dissolving the chlorprothixene (hydrochloride) in the solvent of choice. Chlorprothixene (hydrochloride) is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide, which should be purged with an inert gas. The solubility of chlorprothixene (hydrochloride) in these solvents is approximately 30 mg/ml. Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of chlorprothixene (hydrochloride) can be prepared by directly dissolving the crystalline solid in aqueous buffers. The solubility of chlorprothixene (hydrochloride) in PBS, pH 7.2, is approximately 10 mg/ml. We do not recommend storing the aqueous solution for more than one day. Description 1 Chlorprothixene is a thioxanthine antipsychotic that functions by antagonizing dopamine D2 receptors. It 2 can block a subset of GABAA receptors in rat cortex that is also blocked by clozapine (Item No.
    [Show full text]
  • Thioxanthene Derivates As Sole Anti-Infective Agents
    (19) & (11) EP 2 114 406 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 31/496 (2006.01) A61P 31/04 (2006.01) 25.05.2011 Bulletin 2011/21 A61P 33/00 (2006.01) (21) Application number: 08700129.3 (86) International application number: PCT/DK2008/000005 (22) Date of filing: 07.01.2008 (87) International publication number: WO 2008/080408 (10.07.2008 Gazette 2008/28) (54) THIOXANTHENE DERIVATESAS SOLEANTI- INFECTIVEAGENTS FORUSE INT HE TREATMENT OF INFECTIOUS DISEASES THIOXANTHEN-DERIVATE ALS ALLEINVERTRETER DER ANTIINFEKTIVA ZUR VERWENDUNG IN DER BEHANDLUNG VON INFEKTIONSKRANKHEITEN DÉRIVÉS DE THIOXANTHÈNE COMME SEULS AGENTS ANTIINFECTIEUX POUR LEUR UTILISATION DANS LE TRAITEMENT DES MALADIES INFECTIEUSES (84) Designated Contracting States: • MORTENSEN I ET AL: "THE ANTIBACTERIAL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR ACTIVITY OF THE HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT PSYCHOPHARMACOLOGICAL AGENT RO SE SI SK TR CLOPENTHIXOL AND ITS TWO MAIN METABOLITES" ACTA PATHOLOGICA (30) Priority: 05.01.2007 PCT/DK2007/000006 MICROBIOLOGICASCANDINAVICA, SECTION B, XX, XX, vol. 95B, no. 6, 1987, pages 355-359, (43) Date of publication of application: XP008066133 ISSN: 0108-0180 11.11.2009 Bulletin 2009/46 • KOCISKO ET AL: "Comparison of protease- resistant prion protein inhibitors in cell cultures (60) Divisional application: infected with two strains of mouse and sheep 10181816.9 / 2 301 545 scrapie" NEUROSCIENCE LETTERS, LIMERICK, IE, vol. 388, no. 2, 11 November 2005 (2005-11-11), (73) Proprietor: BKG Pharma ApS pages 106-111, XP005042190 ISSN: 0304-3940 2920 Charlottenlund (DK) • KAISER C ET AL: "Analogs of phenothiazines.
    [Show full text]
  • Antipsychotics
    © Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 | Fax 503-947-1119 Class Update with New Drug Evaluations: Antipsychotics Date of Review: May 2016 End Date of Literature Search: February 2016 New Drugs: brexpiprazole Brand Names (Manufacturer): Rexulti® (Otsuka) cariprazine Vraylar™ (Actavis) Dossiers Received: yes PDL Classes: Antipsychotics, First generation Antipsychotics, Second generation Antipsychotics, Parenteral Current Status of PDL Class: See Appendix 1. Purpose for Class Update: Several new antipsychotic drug products have been approved by the U.S. Food and Drug Administration since these drug classes were last reviewed by the Oregon Health Plan (OHP) Pharmacy and Therapeutics Committee. Research Questions: 1. Is there new comparative evidence of meaningful difference in efficacy or effectiveness outcomes for schizophrenia, bipolar mania or major depressive disorders (MDD) between oral antipsychotic agents (first‐ or second‐generation) or between parenteral antipsychotic agents (first‐ or second‐generation)? 2. Is there new comparative evidence of meaningful difference in harms between oral antipsychotic agents (first‐ or second‐generation) or between parenteral antipsychotic agents (first‐ or second‐generation)? 3. Is there new comparative evidence of meaningful difference in effectiveness or harms in certain subpopulations based on demographic characteristics? Conclusions: There is insufficient evidence of clinically meaningful differences between antipsychotic agents in efficacy or effectiveness or harms between antipsychotic agents for schizophrenia, bipolar mania or MDD. There is insufficient evidence to determine if brexpiprazole and cariprazine offer superior efficacy or safety to other antipsychotic agents for schizophrenia. There is insufficient evidence to determine if brexpiprazole offers superior efficacy or safety to other antipsychotic agents for MDD.
    [Show full text]
  • Acepromazine and Chlorpromazine As Pharmaceutical-Grade Alternatives to Chlorprothixene for Pupillary Light Reflex Imaging in Mice
    Journal of the American Association for Laboratory Animal Science Vol 59, No 2 Copyright 2020 March 2020 by the American Association for Laboratory Animal Science Pages 197–203 Acepromazine and Chlorpromazine as Pharmaceutical-grade Alternatives to Chlorprothixene for Pupillary Light Reflex Imaging in Mice Samantha S Eckley,1 Jason S Villano,1 Nora S Kuo,1 and Kwoon Y Wong2,* Studies of visual responses in isoflurane-anesthetized mice often use the sedative chlorprothixene to decrease the amount of isoflurane used because excessive isoflurane could adversely affect light-evoked responses. However, data are not available to justify the use of this nonpharmaceutical-grade chemical. The current study tested whether pharmaceutical-grade sedatives would be appropriate alternatives for imaging pupillary light reflexes. Male 15-wk-old mice were injected intraperitoneally with 1 mg/kg chlorprothixene, 5 mg/kg acepromazine, 10 mg/kg chlorpromazine, or saline. After anesthetic induction, anes- thesia maintenance used 0.5% and 1% isoflurane for sedative- and saline-injected mice, respectively. A photostimulus (16.0 log photons cm−2 s−1; 470 nm) was presented to the right eye for 20 min, during which the left eye was imaged for consensual pupillary constriction and involuntary pupil drift. Time to immobilization, loss of righting reflex, physiologic parameters, gain of righting reflex, and degree of recovery were assessed also. The sedative groups were statistically indistinguishable for all measures. By contrast, pupillary drift occurred far more often in saline-treated mice than in the sedative groups. Fur- thermore, saline-treated mice took longer to reach maximal pupil constriction than all sedative groups and had lower heart rates compared with chlorpromazine- and chlorprothixene-sedated mice.
    [Show full text]
  • Quinolizidine-Derived Lucanthone and Amitriptyline Analogues Endowed with Potent Antileishmanial Activity
    pharmaceuticals Article Quinolizidine-Derived Lucanthone and Amitriptyline Analogues Endowed with Potent Antileishmanial Activity Michele Tonelli 1,* , Anna Sparatore 2,* , Nicoletta Basilico 3,* , Loredana Cavicchini 3, Silvia Parapini 4 , Bruno Tasso 1 , Erik Laurini 5 , Sabrina Pricl 5,6 , Vito Boido 1 and Fabio Sparatore 1 1 Dipartimento di Farmacia, Università degli Studi di Genova, Viale Benedetto XV, 3, 16132 Genova, Italy; [email protected] (B.T.); [email protected] (V.B.); [email protected] (F.S.) 2 Dipartimento di Scienze Farmaceutiche, Università degli Studi di Milano, Via Mangiagalli 25, 20133 Milano, Italy 3 Dipartimento di Scienze Biomediche Chirurgiche e Odontoiatriche, Università degli Studi di Milano, Via Pascal 36, 20133 Milano, Italy; [email protected] 4 Dipartimento di Scienze Biomediche per la Salute, Università degli Studi di Milano, Via Mangiagalli 31, 20133 Milano, Italy; [email protected] 5 Molecular Biology and Nanotechnology Laboratory (MolBNL@UniTS), DEA, Piazzale Europa 1, 34127 Trieste, Italy; [email protected] (E.L.); [email protected] (S.P.) 6 Department of General Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, 90-236 Lodz, Poland * Correspondence: [email protected] (M.T.); [email protected] (A.S.); [email protected] (N.B.) Received: 4 October 2020; Accepted: 21 October 2020; Published: 25 October 2020 Abstract: Leishmaniases are neglected diseases that are endemic in many tropical and sub-tropical Countries. Therapy is based on different classes of drugs which are burdened by severe side effects, occurrence of resistance and high costs, thereby creating the need for more efficacious, safer and inexpensive drugs.
    [Show full text]
  • N-Alkylamino Derivates of Aromatic, Tricyclic Compounds in the Treatment of Drug-Resistant Protozoal Infections
    Europaisches Patentamt 0 338 532 European Patent Office Qv Publication number: A2 Office europeen des brevets EUROPEAN PATENT APPLICATION 31/54 © Application number: 89107027.8 © mt.ci.4.A61K 31/38 , A61K @ Date of filing: 19.04.89 © Priority: 20.04.88 US 183858 © Applicant: MERRELL DOW 12.09.88 US 243524 PHARMACEUTICALS INC. 2110 East Galbraith Road @. Date of publication of application: Cincinnati Ohio 45215-6300(US) 25.10.89 Bulletin 89/43 © Inventor: Bitonti, Alan J. © Designated Contracting States: 7854 Carraway Court AT BE CH DE ES FR GB GR IT LI LU NL SE Maineville Ohio 45039(US) Inventor: McCann, Peter P. 3782 Cooper Road Cincinnati Ohio 45241 (US) Inventor: Sjoerdsma, Albert 5475 Waring Drive Cincinnati Ohio 45243(US) © Representative: Vossius & Partner Siebertstrasse 4 P.O. Box 86 07 67 D-8000 Munchen 86(DE) © N-alkylamino derivates of aromatic, tricyclic compounds in the treatment of drug-resistant protozoal infections. © Drug-resistant protozoal infection, particularly, drug-resistant malarial infection in humans, can be effectively treated with standard antiprotozoal agents if administered in conjunction with a tricyclic N-aminoalkyi iminodiben- zyl, dibenzylcycloheptane and cycloheptene, phenothiazine, dibenzoxazepine, dibenzoxepine, or thioxanthene derivative. CM < CM CO in oo CO CO LU Xerox Copy Centre EP 0 338 532 A2 N-ALKYLAMINO DERIVATIVES OF AROMATIC, TRICYCLIC COMPOUNDS IN THE TREATMENT OF DRUG- RESISTANT PROTOZOAL INFECTIONS This invention relates to the use of certain N-(aminoalkyl) derivatives of iminodibenzyl, dibenzyl- cycioheptane and cycloheptene, phenothiazine, dibenzoxazepine, dibenzoxepine, and thioxanthene in the treatment of drug-resistant malaria and in the treatment of other drug-resistant protozoal infections.
    [Show full text]
  • < MOH Approved Drugs List >
    Ministry Of Health Directorate General of Medical Supplies Rep_Id : App_Drugs_List_Who.rdf < MOH Approved Drugs List > DATE : 12/08/2009 Page : 1 of 108 VED Flag <S.No> < Item Code > < I T E M D E S C ROF I P- T I O N > < U N I T > DATE : ABC Flag H/C Flag Category : DRUGS 1 Ph. System : GASTRO-INTESTINAL SYSTEM 1 Main Group : ANTACIDS 1 Sub Group : ALUMINIUM COMPOUNDS 1 03000000105 ALUMINIUM HYDROXIDE GEL, DRIED 475 MG. CAPSULE Desirable Cat_C Not H/C Item 2 Sub Group : ANTACID COMPOUND PREPARATIONS 2 02000000079 ANTACID SUSPENSION (ALUMINIUM HYDROXIDE + BOTTLE Desirable MAGNESIUM HYDROXIDE OR TRISILICATE) 100 - 200 Cat_A ML. B0TTLE. H/C Item 3 03000000173 ANTACID TABLET (ALUMINIUM HYDROXIDE + TABLET/CAP Desirable MAGNESIUM HYDROXIDE OR TRISILICATE). Cat_A H/C Item 2 Main Group : ANTISPASMODICS 1 Sub Group : ANTIMUSCARINICS 4 01000000304 HYOSCINE N BUTYLBROMIDE 20MG/ML. 1ML. AMPOULE Essantial Cat_A H/C Item 5 03000000640 HYOSCINE N BUTYL BROMIDE 10MG. TABLET/CAP Essantial Cat_A H/C Item 6 020D0000063 ANTISPASMODIC DROPS 15ML-25ML. BOTTLE Desirable Cat_C Not H/C Item 2 Sub Group : OTHER ANTISPASMODIC AND MOTILITY STIMULANT 7 03000001245 MEBEVERINE HYDROCHLORIDE 100 MG - 135 MG. TABLET/CAP Essantial Cat_B Not H/C Item Ministry Of Health Directorate General of Medical Supplies Rep_Id : App_Drugs_List_Who.rdf < MOH Approved Drugs List > DATE : 12/08/2009 Page : 2 of 108 VED Flag <S.No> < Item Code > < I T E M D E S C ROF I P- T I O N > < U N I T > DATE : ABC Flag H/C Flag Category : DRUGS 1 Ph.
    [Show full text]
  • Concentrations of Antidepressants, Antipsychotics, and Benzodiazepines in Hair Samples from Postmortem Cases
    SN Comprehensive Clinical Medicine (2020) 2:284–300 https://doi.org/10.1007/s42399-020-00235-x MEDICINE Concentrations of Antidepressants, Antipsychotics, and Benzodiazepines in Hair Samples from Postmortem Cases Maximilian Methling1,2 & Franziska Krumbiegel1 & Ayesha Alameri1 & Sven Hartwig1 & Maria K. Parr2 & Michael Tsokos1 Accepted: 30 January 2020 /Published online: 10 February 2020 # The Author(s) 2020 Abstract Certain postmortem case constellations require intensive investigation of the pattern of drug use over a long period before death. Hair analysis of illicit drugs has been investigated intensively over past decades, but there is a lack of comprehensive data on hair concentrations for antidepressants, antipsychotics, and benzodiazepines. This study aimed to obtain data for these substances. A LC-MS/MS method was developed and validated for detection of 52 antidepressants, antipsychotics, benzodiazepines, and metabolites in hair. Hair samples from 442 postmortem cases at the Institute of Legal Medicine of the Charité-University Medicine Berlin were analyzed. Postmortem hair concentrations of 49 analytes were obtained in 420 of the cases. Hair sample segmentation was possible in 258 cases, and the segments were compared to see if the concentrations decreased or increased. Descriptive statistical data are presented for the segmented and non-segmented cases combined (n = 420) and only the segmented cases (n = 258). An overview of published data for the target substances in hair is given. Metabolite/parent drug ratios were investigated for 10 metabolite/parent drug pairs. Cases were identified that had positive findings in hair, blood, urine, and organ tissue. The comprehensive data on postmortem hair concentrations for antidepressants, antipsychotics, and benzodiazepines may help other investigators in their casework.
    [Show full text]
  • ( 12 ) United States Patent
    US010308645B2 (12 ) United States Patent ( 10 ) Patent No. : US 10 ,308 ,645 B2 Liverton et al . (45 ) Date of Patent : Jun . 4 , 2019 ( 54 ) PIPERIDINE OXADIAZOLE AND 8 , 399 ,281 B1 3 / 2013 Patterson et al . 8 , 399 ,494 B2 3 / 2013 Bergman et al. THIADIAZOLE OREXIN RECEPTOR 8 . 466 , 281 B2 6 / 2013 Coleman et al. ANTAGONISTS 8 ,618 , 102 B2 12 / 2013 Coleman et al. 8 ,623 ,863 B2 1 / 2014 Coleman et al. (71 ) Applicant : MERCK SHARP & DOHME CORP ., 8 ,669 , 272 B2 3 / 2014 Breslin et al . 8 ,685 , 961 B2 4 / 2014 Brashear et al. Rahway, NJ (US ) 8 ,710 , 076 B2 4 / 2014 Breslin et al. 8 , 940 , 898 B2 1 / 2015 Kuduk et al . (72 ) Inventors: Nigel Liverton , Harleysville , PA (US ) ; 9 , 029 , 364 B2 5 /2015 Kuduk et al. Scott D . Kuduk , Harleysville , PA (US ) ; 9 , 156 ,819 B2 10 / 2015 Kuduk et al . 9 , 546 , 152 B2 1 /2017 Kuduk et al. Yunfu Luo , Shanghai ( CN ) ; Na Meng , 9 ,550 ,786 B2 1 /2017 Cooke et al . Shanghai (CN ) ; Tingting Yu , Shanghai 9 , 556 , 145 B2 1 / 2017 Kuduk et al . (CN ) 9 ,556 , 190 B2 1 / 2017 Kuduk et al . 9 ,586 ,934 B2 3 / 2017 Kuduk et al. ( 73 ) Assignee : Merck Sharp & Dohme Corp . , 9 , 586 , 950 B2 3 /2017 Kuduk et al. 9 ,617 , 246 B2 4 /2017 Kuduk et al. Rahway , NJ (US ) 9 ,624 , 197 B2 4 / 2017 Kuduk et al . 2009 / 0215822 Al 8 / 2009 Farina et al . ( * ) Notice : Subject to any disclaimer, the term of this 2010 / 0029736 A1 2 / 2010 Cox et al .
    [Show full text]
  • Product Monograph
    PRODUCT MONOGRAPH PrCLOPIXOL® Zuclopenthixol Tablets Lundbeck Std. (10 mg and 25 mg zuclopenthixol as zuclopenthixol hydrochloride) Lundbeck standard PrCLOPIXOL-ACUPHASE® 50 mg/mL Zuclopenthixol Intramuscular Injection (45.25 mg/mL zuclopenthixol as zuclopenthixol acetate) Lundbeck standard PrCLOPIXOL® DEPOT 200 mg/mL Zuclopenthixol Intramuscular Injection (144.4 mg/mL zuclopenthixol as zuclopenthixol decanoate) Lundbeck standard Antipsychotic Agent Lundbeck Canada Inc. Date of Revision: 2600 Alfred-Nobel October 16th, 2020 Suite 400 St-Laurent, QC H4S 0A9 Submission Control No : 171198 Page 1 of 34 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION .........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................4 WARNINGS AND PRECAUTIONS ..................................................................................4 ADVERSE REACTIONS ....................................................................................................9 DRUG INTERACTIONS ..................................................................................................13 DOSAGE AND ADMINISTRATION ..............................................................................14 OVERDOSAGE ................................................................................................................18
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9.486,437 B2 Rogowski Et Al
    USOO94864-37B2 (12) United States Patent (10) Patent No.: US 9.486,437 B2 Rogowski et al. (45) Date of Patent: *Nov. 8, 2016 (54) METHODS OF USING LOW-DOSE DOXEPIN 5,858.412 A 1/1999 Staniforth et al. FOR THE IMPROVEMENT OF SLEEP 5,866,166 A 2f1999 Staniforth et al. 5.948,438 A 9, 1999 Staniforth et al. (71) Applicants: Pernix Sleep, Inc., Morristown, NJ 5,965,166 A 10, 1999 Hunter et al. (US); ProCom One, Inc., San Marcos, 6,103,219 A 8, 2000 Sherwood et al. TX (US) 6,106,865 A 8, 2000 Staniforth et al. 6,211,229 B1 4/2001 Kavey (72) Inventors: Roberta L. Rogowski, Rancho Santa 6,217,907 B1 4/2001 Hunter et al. Fe, CA (US); Susan E. Dubé, Carlsbad, 6,217.909 B1 4/2001 Sherwood et al. CA (US); Philip Jochelson, San Diego, 6,219,674 B1 4/2001 Classen CA (US); Neil B. Kavey, Chappaqua, 6,344,487 B1 2/2002 Kavey 6,358,533 B2 3/2002 Sherwood et al. NY (US) 6,391,337 B2 5, 2002 Hunter et al. (73) Assignees: Pernix Sleep, Inc., Morristown, NJ 6,395,303 B1 5, 2002 Staniforth et al. (US); ProCom One, Inc., San Marcos, 6,403,597 B1 6/2002 Wilson et al. 6,407,128 B1 6/2002 Scaife et al. TX (US) 6,471.994 B1 10/2002 Staniforth et al. 6,521,261 B2 2/2003 Sherwood et al. (*) Notice: Subject to any disclaimer, the term of this 6,584,472 B2 6/2003 Classen patent is extended or adjusted under 35 6,683,102 B2 1/2004 Scaife et al.
    [Show full text]